Fuan Pharmaceutical (Group) Co., Ltd. (SHE:300194)
China · Delayed Price · Currency is CNY 3.910
-0.040 (-1.01%)
Sep 10, 2026, 1:45 PM CST
SHE:300194 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 4,699 | 5,270 | 5,306 | 5,211 | 4,283 | 6,091 | |
Market Cap Growth | -14.13% | -0.67% | 1.83% | 21.67% | -29.69% | 3.85% |
Enterprise Value | 4,396 | 5,105 | 5,053 | 5,298 | 4,461 | 6,503 |
Last Close Price | 3.95 | 4.37 | 4.33 | 4.20 | 3.41 | 4.85 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 87.16 | 68.45 | 18.96 | 22.47 | 20.93 | - |
Forward PE | - | 95.55 | 95.55 | 95.55 | 95.55 | 95.55 |
PS Ratio | 2.84 | 3.03 | 2.22 | 1.97 | 1.77 | 2.48 |
PB Ratio | 1.07 | 1.21 | 1.21 | 1.26 | 1.09 | 1.58 |
P/TBV Ratio | 1.23 | 1.40 | 1.44 | 1.50 | 1.39 | 2.14 |
P/FCF Ratio | 13.34 | 25.85 | 85.87 | 45.99 | - | - |
P/OCF Ratio | 10.80 | 16.88 | 17.48 | 15.84 | 12.62 | 23.69 |
PEG Ratio | - | 1.43 | 1.43 | 1.43 | 1.43 | 1.43 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 2.65 | 2.94 | 2.11 | 2.00 | 1.84 | 2.65 |
EV/EBITDA Ratio | 14.21 | 19.59 | 11.33 | 13.49 | 15.70 | 20.20 |
EV/EBIT Ratio | 42.47 | 90.06 | 20.33 | 28.71 | 44.50 | 44.06 |
EV/FCF Ratio | 12.48 | 25.04 | 81.76 | 46.76 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.14 | 0.18 | 0.16 | 0.22 | 0.18 | 0.23 |
Debt / EBITDA Ratio | 1.92 | 3.06 | 1.58 | 2.27 | 2.51 | 2.81 |
Debt / FCF Ratio | 1.69 | 3.93 | 11.42 | 7.88 | - | - |
Net Debt / Equity Ratio | -0.07 | -0.05 | -0.04 | -0.02 | 0.00 | -0.02 |
Net Debt / EBITDA Ratio | -1.00 | -0.91 | -0.38 | -0.26 | 0.04 | -0.30 |
Net Debt / FCF Ratio | -0.86 | -1.16 | -2.76 | -0.92 | -0.24 | 0.62 |
Asset Turnover | 0.28 | 0.30 | 0.40 | 0.45 | 0.42 | 0.42 |
Inventory Turnover | 1.47 | 1.51 | 1.51 | 1.79 | 1.58 | 1.53 |
Quick Ratio | 1.35 | 1.52 | 0.95 | 1.16 | 0.90 | 1.10 |
Current Ratio | 2.23 | 2.32 | 1.68 | 1.78 | 1.50 | 1.62 |
Return on Equity (ROE) | 1.34% | 1.75% | 6.51% | 5.79% | 5.14% | -14.48% |
Return on Assets (ROA) | 1.11% | 0.60% | 2.60% | 1.95% | 1.08% | 1.58% |
Return on Invested Capital (ROIC) | 2.10% | 1.25% | 5.35% | 3.72% | 2.60% | 3.68% |
Return on Capital Employed (ROCE) | 2.20% | 1.20% | 5.20% | 3.90% | 2.20% | 3.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 1.27% | 1.46% | 5.27% | 4.45% | 4.78% | -4.87% |
FCF Yield | 7.50% | 3.87% | 1.17% | 2.17% | -1.02% | -2.56% |
Dividend Yield | 1.80% | 1.60% | 1.16% | 1.19% | 1.47% | - |
Payout Ratio | 170.61% | 136.36% | 30.09% | 40.53% | 13.73% | - |
Buyback Yield / Dilution | -16.46% | -10.06% | 4.46% | -1.40% | -1.34% | -2.10% |
Total Shareholder Return | -14.65% | -8.46% | 5.61% | -0.20% | 0.13% | -2.10% |